Search
forLearn
5 / 801 resultslearn retinoic acid
learn biovolume 128
learn calcium ascorbate
learn Stem Cell Factor
Research
5 / 1000+ resultsresearch Virtual memory is a big hairy deal
CD8+ virtual memory T cells may cause hair loss in alopecia areata.
research 042 Characterization of Pathogenic CD8+ T Cells in an adoptive transfer Mouse Model of Alopecia Areata in C3H/HeJ mice
Certain CD8+ T cells attack hair follicles in alopecia areata, suggesting they could be targeted for treatment.
research Editors’ Picks
A specific type of immune cell plays a key role in causing alopecia areata and could be a target for treatment.
research iNKT cells ameliorate human autoimmunity: Lessons from alopecia areata
iNKT cells can help prevent and treat alopecia areata by promoting hair regrowth.
research IL-15 in T-Cell Responses and Immunopathogenesis
IL-15 is key for T cell function and could help improve treatments for immune-related diseases.
Community Join
5 / 1000+ resultscommunity mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community PTD-DBM Update: Q&A With Dr. Kang-Yell Choi
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
community Scientists discover new T cell treatment that could regrow hair
Scientists discovered a new T cell treatment that could regrow hair. Users are skeptical but hopeful, with some relying on finasteride and minoxidil in the meantime.
community TDM-105795 phase 2 results are in!
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.